Cancer Epidemiology Biomarkers & Prevention, Vol 6, Issue 8 603-610, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer

TW Kensler, SJ Gange, PA Egner, PM Dolan, A Munoz, JD Groopman, AE Rogers and BD Roebuck
Department of Environmental Health Sciences, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205, USA. tkensler@phnet.sph.jhu.edu

Studies in animals and humans have established serum aflatoxin-albumin adducts as biomarkers of exposure to aflatoxin B1 (AFB1), a food-borne hepatocarcinogen. To assess the utility of measurements of aflatoxin-albumin adducts to predict risk of hepatocellular carcinoma (HCC), 123 male F344 rats were dosed with 20 microg of AFB1 daily for 5 weeks after randomization into three groups: no intervention; delayed-transient (500 ppm of oltipraz, weeks 2 and 3 relative to AFB1); or persistent (500 ppm oltipraz, weeks -1 to 5). Serial blood samples were collected from each animal at weekly intervals throughout aflatoxin B1 exposure and assayed for levels of aflatoxin-albumin by radioimmune assay. Area under the curve (AUC) values for aflatoxin-albumin adducts decreased 20 and 39% in the delayed-transient and persistent oltipraz intervention groups, respectively, as compared to no intervention. Similarly, the total incidence of HCC dropped from 83 to 60% (P = 0.03) and 48% (P < 0.01) in these groups. Tumor multiplicity was also reduced in the two oltipraz intervention groups, whereas time to HCC was increased. Mononuclear cell leukemia, a common neoplasm in F344 rats, was seen in 39% of the control animals, whereas the two oltipraz interventions reduced incidence to 18% (P = 0.05) and 13% (P = 0.01), respectively. Overall, a significant association was seen between biomarker AUC and risk of HCC (P = 0.01). However, when the predictive value of aflatoxin-albumin adducts was assessed within treatment groups, there was no association between AUC and risk of HCC (P = 0.56). Thus, aflatoxin-albumin adducts can be useful for monitoring population-based changes induced by interventions, such as in chemoprevention trials, but have limited utility in identifying individuals destined to develop HCC. As a consequence, the use of this biomarker in quantitative risk assessment should be pursued cautiously.

This article has been cited by other articles:

				T. W. Kensler, J.-G. Chen, P. A. Egner, J. W. Fahey, L. P. Jacobson, K. K. Stephenson, L. Ye, J. L. Coady, J.-B. Wang, Y. Wu, et al. Effects of Glucosinolate-Rich Broccoli Sprouts on Urinary Levels of Aflatoxin-DNA Adducts and Phenanthrene Tetraols in a Randomized Clinical Trial in He Zuo Township, Qidong, People's Republic of China Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2605 - 2613. [Abstract] [Full Text] [PDF]

				B. D. Roebuck, T. J. Curphey, Y. Li, K. J. Baumgartner, S. Bodreddigari, J. Yan, S. J. Gange, T. W. Kensler, and T. R. Sutter Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz Carcinogenesis, December 1, 2003; 24(12): 1919 - 1928. [Abstract] [Full Text] [PDF]

				C.P. Wild and P.C. Turner The toxicology of aflatoxins as a basis for public health decisions Mutagenesis, November 1, 2002; 17(6): 471 - 481. [Abstract] [Full Text] [PDF]

				N. V. Dimitrov, C. M. Leece, E. R. Tompkins, E. Seymour, M. Bennink, J. Gardiner, J. Crowell, E. Hawk, M. Nashawaty, and J. L. Bennett Oltipraz Concentrations in Plasma, Buccal Mucosa Cells,and Lipids: Pharmacological Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 201 - 207. [Abstract] [Full Text]

				F. P. Perera Molecular Epidemiology: On the Path to Prevention? J Natl Cancer Inst, April 19, 2000; 92(8): 602 - 612. [Abstract] [Full Text] [PDF]

				J.-S. Wang, X. Shen, X. He, Y.-R. Zhu, B.-C. Zhang, J.-B. Wang, G.-S. Qian, S.-Y. Kuang, A. Zarba, P. A. Egner, et al. Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China J Natl Cancer Inst, February 17, 1999; 91(4): 347 - 354. [Abstract] [Full Text] [PDF]

				J. D. Groopman and T. W. Kensler The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight? Carcinogenesis, January 1, 1999; 20(1): 1 - 11. [Full Text] [PDF]